Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report issued on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $50.00 price target on the stock.

DMRA has been the subject of several other research reports. TD Cowen began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They set a “buy” rating for the company. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Finally, Wedbush reiterated an “outperform” rating and issued a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.38.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of NASDAQ DMRA opened at $28.33 on Monday. The company has a 50 day simple moving average of $25.84 and a 200 day simple moving average of $25.98. The firm has a market cap of $1.74 billion, a PE ratio of -5.08 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $40,000. Virtu Financial LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $49,000. Two Sigma Investments LP acquired a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $76,000. Connective Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $100,000. Finally, Geode Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $266,000. 14.20% of the stock is owned by institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.